Ocuphire's lead product is Nyxol, a preservative-free ophthalmic formulation of phentolamine mesylate being developed as a once-daily eye drop for night vision disturbances (NVD), glaucoma, reversal of mydriasis and a fixed-dose combo for presbyopia. Nyxol has safety and efficacy data from five Phase 1 and Phase 2 trials and has demonstrated moderately reduced pupil size, significant intraocular pressure lowering, and convenient once-daily dosing. The company is enrolling double-masked, randomized, placebo-controlled Phase 2 trials in glaucoma (ORION-1) and reversal of mydriasis (MIRA-1), and is preparing a Phase 3 study in NVD (LYNX-1). Clinical results from ORION-1 and MIRA-1 are expected later this year; as of mid-July the company had enrolled more than 50% of the 40 patients in ORION-1. Ocuphire has built management, board, clinical and manufacturing partners, and a medical advisory board of ophthalmic KOLs to support development and commercialization. Proceeds from recent financing will be used to fund multiple late Phase 2 clinical trials of Nyxol.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2019